摘要
目的探讨吡美莫司乳膏对敏感性皮肤的疗效及其机制。方法采用烧灼感或瘙痒程度评分及参照由温度敏感型瞬时受体电位通道建立的痛痒觉基本规则和分子底物(即分子精神物理学)方法,评估外用1%吡美莫司乳膏治疗前、后敏感性皮肤患者面部烧灼感、瘙痒程度及皮肤感觉的变化。结果外用1%吡美莫司乳膏可终止或显著降低32例敏感性皮肤患者面部烧灼感或瘙痒程度评分(P<0.05)。20例(62.5%)患者外用1%吡美莫司乳膏后,应用部位产生辣椒素样效应(即灼热感后随之瘙痒和/或烧灼感迅速改善),6例(18.8%)患者产生樟脑醇样效应(即温感后随之瘙痒迅速改善),6例(18.8%)患者外用1%吡美莫司乳膏后缺乏辣椒素样反应和/或樟脑醇样反应。结论外用1%吡美莫司乳膏可终止或降低敏感性皮肤患者的神经感觉伤害症状(即烧灼和瘙痒),作用机制与调节皮肤感觉神经上的瞬时受体电位香草类受体1功能有关。
Objective To investigate the effectiveness of pimecrolimus cream 1% for sensitive skin in adult women and its underlying mechanisms. Methods The changes of subjective symptoms and signs were evaluated before and after the application of pimecrolimus cream 1% based on the severity of pruritus （SP） and severity of burning sensation （SB） scores, and on a basic syntax and molecular substrate （ molecular psycho- physics） of nociception and pruriception established by temperature-sensitive transient receptor potential （TRP） channels. Results The SP and SB scores were significantly decreased in 32 patients with sensitive skin after using topical pimecrolimus cream 1% （P 〈 0.05 ）. Twenty （62.5 % ） patients showed positive cap- saiein-like response （i. e. burning with consequent rapid amelioration of pruritus or burning sensation） and 6 （ 18.8 % ） showed positive camphor-like response （ i. e. warming with consequent rapid amelioration of pruri- tus） on application sites after using the topical pimecrolimus cream 1% , and 6 （ 18.8 % ） showed negative capsaicin-like response and/or negative camphor-like response. Conclusions Pimecrolimus may rapidly inhibitor alleviate itch or burning sensation of patients with sensitive skin. The therapeutic effect of pimecrolimus is relevant to the mechanisms that activate or sensitize transient receptor potential vanilloid 1 （ TRPV1 ） and de- sensitizes TRPV1 in the skin sensory afferents.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2012年第4期375-378,共4页
Acta Academiae Medicinae Sinicae
基金
教育部教育振兴行动计划特殊专项("九八五"工程)~~
关键词
吡美莫司
敏感性皮肤
瘙痒
烧灼
瞬时受体电位香草类受体1
pimecrolimus
sensitive skin
pruritus
burning sensation
transient receptor potential vanilloid receptor 1
